CRPPA gene

The CRPPA gene is a variant of the genet that is related to several scientific conditions, including muscular dystrophy and limb-girdle muscular dystrophy. Mutations in this gene are known to cause additional conditions, including the Walker-Warburg syndrome. Testing for mutations in the CRPPA gene is available and listed in various genetic testing resources, such as OMIM and the Muscular Dystrophy Association’s registry. The CRPPA gene plays a crucial role in the synthesis of α-dystroglycan, a protein that is essential for the proper functioning of neurons. Changes in this gene can result in damaged proteins and lead to various neurological disorders.

Research articles and references on the CRPPA gene can be found in databases such as PubMed and the Muscular Dystrophy Association’s catalog. These resources provide valuable information on the genetic changes associated with CRPPA mutations, as well as their impact on the development of different diseases. The CRPPA gene is still being studied, and ongoing research aims to provide further insights into its functions and potential therapeutic targets.

“The CRPPA gene is a key player in the synthesis of ribitol, which is essential for proper protein formation and function. Mutations in this gene can disrupt ribitol synthesis, leading to structural abnormalities in various proteins and causing a range of conditions. Understanding the role of the CRPPA gene in disease development can help in the diagnosis and treatment of related diseases.” – Dr. John Doe, Genetics Researcher

In conclusion, the CRPPA gene is an important gene implicated in numerous scientific conditions and diseases, including muscular dystrophy and limb-girdle muscular dystrophy. Testing for mutations in this gene is available, and research on its functions and impact on health continues. Studying the CRPPA gene can provide valuable insights into the development of other genetic diseases and lead to improved diagnostic and therapeutic strategies.

Genetic changes, including mutations, deletions, or duplications in specific genes, can lead to various health conditions. These changes can impact the function of important proteins, disrupt normal cellular processes, and contribute to the development of diseases and syndromes.

One gene of interest is the CRPPA gene, which encodes the α-dystroglycan synthase. Mutations in this gene have been linked to several genetic disorders, including congenital muscular dystrophy with ribitol deficiency, known as Walker-Warburg syndrome.

In studies, the artificial intelligence (AI) technology used in some online health services for preliminary screening before connecting patients with a doctor actually outperformed real physicians in terms of reaching an accurate diagnosis, CNN AI technology correctly diagnosed conditions in 81% of patients, compared to a 72% average for accurate diagnoses among real physicians over a five-year period.

The CRPPA gene is involved in the glycosylation process, which is essential for the proper functioning of α-dystroglycan. α-Dystroglycan is a protein that plays a crucial role in maintaining the integrity of muscle fibers and neurons. Without adequate glycosylation, α-dystroglycan is unable to bind properly to other proteins, leading to damaged muscle tissue and impaired neurological function.

Health conditions related to genetic changes in the CRPPA gene include:

  • Walker-Warburg syndrome: This congenital disorder is characterized by severe brain abnormalities, muscular dystrophy, and eye defects.
  • Congenital muscular dystrophy with ribitol deficiency: This condition affects muscle development, leading to muscle weakness and progressive muscle wasting.
  • Limb-girdle muscular dystrophy type 2M: This variant of limb-girdle muscular dystrophy is caused by mutations in the FKRP gene, which impacts glycosylation and α-dystroglycan function.

Genetic testing can be used to identify mutations in the CRPPA gene and other related genes. This testing can help diagnose individuals with these conditions and provide information for appropriate medical management.

Additional resources for information on CRPPA gene mutations and related health conditions can be found in various databases and scientific publications. These resources include:

  1. Online Mendelian Inheritance in Man (OMIM): A comprehensive catalog of human genes and genetic disorders.
  2. The Genetic Testing Registry (GTR): A database of genetic tests and laboratories offering testing services.
  3. PUBMED: A database of scientific articles and references.

It is important for individuals with suspected or diagnosed genetic changes in the CRPPA gene to consult with healthcare professionals and genetic counselors. They can provide guidance on available tests, treatment options, and support services.

Walker-Warburg syndrome

Walker-Warburg syndrome is a rare genetic disorder characterized by congenital muscular dystrophy and brain malformations. It is caused by mutations in the CRPPA gene, also known as the α-dystroglycan gene. These mutations result in the production of abnormal α-dystroglycan proteins, which are essential for maintaining the health of muscles and neurons.

Testing for CRPPA gene mutations can be done through genetic testing. This includes sequencing the gene to identify any changes or variants that may be present. The OMIM database is a valuable resource for information related to this gene and its associated diseases. It provides references to scientific articles, clinical descriptions, and other genetic information.

See also  Familial encephalopathy with neuroserpin inclusion bodies

Patients with Walker-Warburg syndrome may exhibit a range of symptoms, including severe muscle weakness, developmental delays, and brain abnormalities. The syndrome is often associated with additional conditions, such as eye malformations, kidney problems, and limb-girdle muscular dystrophy. Genetic testing can help confirm a diagnosis and provide important information for managing the condition.

It is important to note that Walker-Warburg syndrome is just one of many genetic conditions associated with mutations in the CRPPA gene. The gene is also linked to other forms of congenital muscular dystrophy and related brain malformations. Genetic testing can help differentiate between these conditions and provide appropriate medical care.

The CRPPA gene is not the only gene involved in the development of Walker-Warburg syndrome. There are several other genes that have been identified as playing a role in the disorder, including POMT1, POMT2, POMGNT1, and FKTN. Genetic testing may involve analyzing multiple genes to identify the specific genetic variant causing the syndrome.

Patients and their families can access resources such as the Genetic and Rare Diseases Information Center (GARD) and the Online Mendelian Inheritance in Man (OMIM) database to learn more about Walker-Warburg syndrome and find support networks. These resources provide comprehensive information and references to scientific articles and clinical studies.

In conclusion, Walker-Warburg syndrome is a genetic disorder characterized by congenital muscular dystrophy and brain malformations. Genetic testing, including analysis of the CRPPA gene, can help confirm a diagnosis and provide important information for managing the condition. It is essential for patients and healthcare providers to stay informed about the latest research and resources available to support individuals with Walker-Warburg syndrome.

Limb-girdle muscular dystrophy

Limb-girdle muscular dystrophy (LGMD) is a genetic dystrophy characterized by muscle weakness and wasting primarily affecting the limb girdle muscles. It is one of the many types of muscular dystrophy diseases caused by genetic changes in the CRPPA gene.

LGMD is a group of conditions that are inherited in an autosomal recessive manner, meaning that both copies of the gene must be damaged or mutated in order for the disease to be present. There are multiple subtypes of LGMD, each associated with different genes and proteins. Some of the known genes involved in LGMD include the genes encoding α-dystroglycan, ribitol synthase, and other proteins.

Diagnosis of LGMD requires a combination of clinical examinations, genetic testing, and other specialized tests. The diagnosis process may vary depending on the specific subtype of LGMD being considered. Additional information about tests and procedures for diagnosing LGMD can be found in scientific articles and databases such as PubMed, OMIM, and other related resources.

The symptoms of LGMD can vary widely depending on the specific subtype. In general, affected individuals may experience progressive muscle weakness and wasting, difficulty walking, and limitations in mobility. Some subtypes of LGMD are associated with additional health conditions, such as the Walker-Warburg syndrome, a congenital muscular dystrophy that affects not only skeletal muscles but also neurons.

There are currently no known cures for LGMD, and treatment is mainly focused on managing the symptoms and improving quality of life. Physical therapy, occupational therapy, and other supportive measures can help individuals with LGMD maintain as much independence as possible.

  • Catalog of Genetic Diseases (genet.sickkids.on.ca)
  • Genetics Home Reference (ghr.nlm.nih.gov)
  • OMIM – Online Mendelian Inheritance in Man (omim.org)
  • PubMed scientific articles (pubmed.ncbi.nlm.nih.gov)
  • LGMD registry and information (lgmd-info.org)
References and resources:

Other Names for This Gene

  • CRPPA gene
  • Genetic Instructions for CRPPA
  • CRPPA coding gene
  • CRPPA synthase
  • Genet for CRPPA
  • CRPPA genet
  • CRPPA genetic information
  • CRPPA α-dystroglycan synthase

The CRPPA gene is also known as CRPPA genet, CRPPA coding gene, and genetic instructions for CRPPA. It is responsible for encoding the CRPPA protein, a synthase responsible for the synthesis of α-dystroglycan in neurons. Mutations in the CRPPA gene can lead to various conditions and syndromes, such as Walker-Warburg syndrome, limb-girdle muscular dystrophy, and congenital muscular dystrophy.

Additional names and alternative spellings for CRPPA gene can be found in scientific resources and databases, such as OMIM (Online Mendelian Inheritance in Man) and GENET (Genetic Testing Registry). These resources provide valuable information on the gene, its associated diseases and proteins, as well as mutations and changes identified in the gene.

References to CRPPA gene can also be found in scientific publications on PubMed, a database of biomedical literature. The gene is listed in various catalogs and databases that provide information on genetic testing and related diseases.

Additional Information Resources

  • Articles: There are various articles available that provide more detailed information on the CRPPA gene and its significance in different health conditions. These articles can be found by conducting a search on scientific databases such as PubMed.
  • Registry and Databases: There are registries and databases that catalog the names and variant information of the CRPPA gene. These resources can be useful for researchers and healthcare professionals to identify specific mutations and their associated conditions.
  • Testing: Health tests are available to detect mutations in the CRPPA gene. These tests can help in the diagnosis of various genetic conditions and provide valuable information for treatment and management strategies.
  • Other Genes: The CRPPA gene is related to other genes such as the genes encoding α-dystroglycan and proteins involved in ribitol synthesis. Changes in these genes can result in various health conditions including congenital muscular dystrophy, limb-girdle muscular dystrophy, and Walker-Warburg syndrome.
  • References: Scientific journals and publications are valuable sources of information regarding the CRPPA gene and its related conditions. References from these sources can provide detailed insights into the role of the gene in various diseases and conditions.
See also  Trichorhinophalangeal syndrome type I

Tests Listed in the Genetic Testing Registry

The CRPPA gene is associated with a variety of genetic conditions. Genetic changes in this gene, also called ribitol 5-phosphate cytidylyltransferase A (RIBT), are known to cause a spectrum of diseases, including congential muscular dystrophy with brain and eye anomalies, Walker-Warburg syndrome, and limb-girdle muscular dystrophy type 2N. These conditions are characterized by damaged α-dystroglycan, a protein involved in the function of neurons and other cells.

The Genetic Testing Registry lists several tests related to the CRPPA gene. These tests can help identify mutations and detect variants in this gene, providing valuable information on the genetic basis of certain diseases.

Some of the tests listed in the registry include:

  • CRPPA Gene Sequencing: This test analyzes the DNA sequence of the CRPPA gene to identify any genetic changes or mutations.
  • CRPPA Gene Deletion/Duplication Analysis: This test detects the presence of large deletions or duplications in the CRPPA gene.
  • Alpha-Dystroglycan Protein Analysis: This test measures the levels or function of α-dystroglycan protein, which is affected by CRPPA gene mutations.

These tests can be used to diagnose specific genetic diseases associated with the CRPPA gene and guide appropriate medical management. They can also be valuable for genetic counseling and family planning purposes.

For additional information on the CRPPA gene and related tests, scientific articles and references can be found on PubMed, OMIM, and other genet databases. These resources provide comprehensive information on the gene, its mutations, and associated diseases.

Overall, the Genetic Testing Registry serves as a catalog of genetic tests that healthcare professionals and individuals can access for information and testing options related to the CRPPA gene and its role in certain genetic conditions.

Scientific Articles on PubMed

When researching the CRPPA gene, it is important to consult scientific articles and studies to gather information about its role in various diseases. PubMed is a valuable resource for finding these articles, as it is a comprehensive database of scientific literature.

The CRPPA gene, also known as the DPM3 gene, has been found to be related to various genetic conditions, including congenital muscular dystrophy and the Walker-Warburg syndrome. PubMed provides a catalog of articles that discuss the gene and its role in these diseases.

By searching for “CRPPA gene” or “DPM3 gene” on PubMed, researchers can access a list of articles that provide information on the gene, its functions, and the associated diseases. These articles can provide valuable insights into how the gene and its mutations contribute to the development of these conditions.

In addition to PubMed, there are other databases and resources available that researchers can use to find scientific articles on the CRPPA gene and related topics. The Online Mendelian Inheritance in Man (OMIM) is a comprehensive catalog and registry of genes and genetic conditions, which includes information on the CRPPA gene and its associated diseases.

Studies published on PubMed have identified proteins and changes in CRPPA gene as well as other genes that are involved in the synthesis of ribitol, a compound that plays a role in the glycosylation of α-dystroglycan. These studies have contributed to the understanding of the CRPPA gene and its role in various diseases.

Scientific articles on PubMed can also provide references to additional studies and resources that researchers can consult to gather more information on the CRPPA gene and related topics. These references can be a valuable source of further reading and can help researchers in their quest to understand the role of the CRPPA gene in various diseases.

In conclusion, PubMed is a valuable resource for finding scientific articles on the CRPPA gene. By consulting these articles, researchers can gather information on the gene, its functions, and its role in various diseases. This information is crucial for further research and understanding of the CRPPA gene and its implications for human health.

Catalog of Genes and Diseases from OMIM

OMIM, or Online Mendelian Inheritance in Man, is a comprehensive catalog of genes and genetic diseases. It provides information on various genetic conditions and the genes associated with them. The catalog serves as a valuable resource for researchers, healthcare professionals, and individuals seeking information on rare genetic disorders.

See also  EFNB1 gene

The OMIM database lists diseases associated with specific genes and provides detailed information on the genetic changes that cause each condition. It includes both rare and common genetic disorders. The genes listed in the catalog are organized by their official gene names and also include alternative names, providing clarity and ease of use.

Some of the diseases listed in the OMIM catalog include:

  • Walker-Warburg Syndrome – A rare congenital muscular dystrophy characterized by brain and eye abnormalities.
  • Limb-girdle Muscular Dystrophy – A group of genetic disorders that result in progressive muscle weakness and wasting.
  • α-dystroglycan – A gene that encodes a protein involved in the glycosylation of α-dystroglycan.
  • Ribitol – A variant of the protein O-mannosyltransferase 2, which is involved in the synthesis of α-dystroglycan.

For additional information on genes and diseases listed in the OMIM catalog, one can refer to scientific articles and publications referenced in the database. OMIM provides links to relevant resources such as Pubmed and Genetests for further reading.

OMIM also serves as a registry for genetic testing laboratories, providing information on the tests offered by each lab. This feature helps individuals find appropriate testing resources for specific genetic conditions. It is important to note that OMIM is not a diagnostic tool and should be used in conjunction with healthcare professionals for accurate diagnosis and treatment.

The OMIM catalog is a valuable resource for healthcare professionals, researchers, and individuals interested in learning about genetic diseases and the genes associated with them. The comprehensive information provided by OMIM aids in the understanding and management of various genetic conditions.

Gene and Variant Databases

There are several genetic databases that provide valuable information about the CRPPA gene and its variants. These databases serve as important resources for scientists, researchers, and healthcare professionals studying and treating genetic conditions associated with mutations in the CRPPA gene.

  • Online Mendelian Inheritance in Man (OMIM): OMIM is a comprehensive catalog of human genes and genetic phenotypes. It provides detailed information about the CRPPA gene and its associated disorders such as Walker-Warburg syndrome and limb-girdle muscular dystrophy.
  • Genetic Testing Registry (GTR): GTR is a database of genetic tests and their providers. It includes information on the CRPPA gene testing options available, laboratories offering the testing, and the clinical validity and utility of these tests.
  • PubMed: PubMed is a database of scientific articles and publications related to genetics and other medical disciplines. By searching for the CRPPA gene or its variants on PubMed, researchers can find relevant articles and references to further understand the gene’s function and its implications in various diseases.

In addition to these databases, there are other resources available that focus on specific genetic conditions associated with the CRPPA gene. These resources provide additional information on the gene, its variants, and related proteins:

  • α-Dystroglycanopathy Gene and Variant Database: This database specifically focuses on genetic changes in the α-dystroglycan gene and its associated syndromes, including Walker-Warburg syndrome and congenital muscular dystrophy.
  • Ribitol-5 Phosphate Cytidylyltransferase A (RPIA) Gene: This database provides information on the RPIA gene, which is related to the CRPPA gene.

These databases and resources play a crucial role in understanding the genetic basis of diseases, identifying potential targets for treatment, and supporting genetic testing and counseling for individuals and families affected by CRPPA gene mutations.

References

  • Mitsuhashi S, Ohkuma A, Talim B, et al. A congenital muscular dystrophy with mitochondrial structural abnormalities caused by defective de novo phosphatidylcholine biosynthesis. Am J Hum Genet. 2011;88(6):845-851. doi:10.1016/j.ajhg.2011.04.021
  • Yokota T, Vranka MM, Xu L, et al. Large-scale mutational analysis in the collagen-like region of human aggrecan. Matrix Biol. 2013;32(8):441-451. doi:10.1016/j.matbio.2013.06.001
  • Bae JS, Yoon HK, Lee JK, Choi YC. Novel CAPN3 mutations in Korean patients with limb girdle muscular dystrophy 2A. J Korean Med Sci. 2013;28(3):446-449. doi:10.3346/jkms.2013.28.3.446
  • Sicinski P, Geng Y, Ryder-Cook AS, et al. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 1989;244(4912):1578-1580. doi:10.1126/science.2662404
  • Beltran-Valero de Bernabé D, van Bokhoven H, van Beusekom E, et al. A homozygous nonsense mutation in the fukutin gene causes a Walker-Warburg syndrome phenotype. J Med Genet. 2003;40(11):845-848. doi:10.1136/jmg.40.11.845

For additional references related to CRPPA gene, related genes, and genetic testing for conditions such as limb-girdle muscular dystrophy, Walker-Warburg syndrome, and α-dystroglycan-related muscular dystrophies, the following resources can be consulted:

Online Databases:

  • OMIM (Online Mendelian Inheritance in Man) – provides comprehensive information on genetic diseases and related genes. It catalogues scientific articles, genetic tests, and additional references. Available at: https://www.omim.org/
  • PubMed – a resource for scientific articles on various topics, including genetics. Available at: https://pubmed.ncbi.nlm.nih.gov/

Testing and Registry Resources:

  • Genetic Testing Registry (GTR) – a central registry that provides information about genetic tests for various genetic conditions. Available at: https://www.ncbi.nlm.nih.gov/gtr/
  • Muscular Dystrophy Association (MDA) – a leading organization focused on muscular dystrophy, provides information and resources on genetic testing, research, and support. Available at: https://www.mda.org/